^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SEZ6 expression

    i
    Other names: SEZ6, Seizure Related 6 Homolog, Seizure Protein 6 Homolog, Seizure Related 6 Homolog (Mouse), HSEZ-6, BSRPC, SEZ-6
    Entrez ID:
    124925
    3ms
    Overexpression of SEZ6L2 and Immune Infiltration in Cancer Based on Gene Image Diagnosis. (PubMed, Skin Res Technol)
    Increased SEZ6L2 mRNA expression in breast invasive carcinoma was significantly associated with negative prognosis and immune invasion. SEZ6L2 may be a novel prognostic biomarker and a potential immunotherapeutic target in BRCA.
    Journal • BRCA Biomarker • IO biomarker
    |
    BRCA (Breast cancer early onset)
    |
    SEZ6 expression
    3ms
    Detection of SEZ6, a therapeutic target, in medullary thyroid carcinoma. (PubMed, J Clin Endocrinol Metab)
    SEZ6 may serve as a novel biomarker for MTCs. Although SEZ6 lacks any prognostic values in MTC, its positivity in 91% to 93% of MTCs, including MTCs without RET and RAS mutations, renders SEZ6-targetted antibody-drug conjugate therapy a promising targeted therapy for MTCs.
    Journal
    |
    SEZ6 (Seizure Related 6 Homolog)
    |
    RAS mutation • RET mutation • SEZ6 expression
    |
    ABBV-011
    8ms
    Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=350, Recruiting, AbbVie | Trial completion date: Oct 2025 --> May 2027
    Trial completion date • Adverse events • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
    |
    EGFR mutation • IDH wild-type • SEZ6 expression
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    9ms
    Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=350, Recruiting, AbbVie | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Dec 2026 --> Oct 2025
    Trial completion date • Trial primary completion date • Adverse events • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • SEZ6 (Seizure Related 6 Homolog)
    |
    EGFR mutation • IDH wild-type • SEZ6 expression
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706
    over1year
    Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors (ESMO 2023)
    The study will evaluate the preliminary safety, tolerability, pharmacokinetics (PK), and antitumor activity of ABBV-706 as monotherapy and in combination with budigalimab (a PD-1 inhibitor), carboplatin, or cisplatin, and determine the recommended phase 2 dose (RP2D) of ABBV-706. Tumor tissue submission for retrospective SEZ6 expression analysis is required. The study began in December 2022 and enrollment is ongoing.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    SEZ6 (Seizure Related 6 Homolog)
    |
    SEZ6 expression
    |
    cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706